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Abstract: Immunotherapy with dendritic cells (DC) may constitute a new and advantageous option for pa-
tients with chronic myeloid leukemia (CML) who respond to therapy with tyrosine kinase inhibitors (TKI),
but do not reach complete cytogenetic or molecular remission. In this study, we evaluated the immunopheno-
type of DC generated from monocytes (Mo-DC) of patients with CML and the influence of TKI therapy on
the results of CML-DC generation. We also measured the percentages of T regulatory cells (Tregs) as well as
Th17 cells in 19 untreated patients suffering from CML, and in 28 CML patients treated with TKI. We found
that DC can be reliably generated from the peripheral blood CD14+ cells of untreated CML patients. But we
observed a persistent expression of CD14 monocyte marker on DC from CML patients, together with lower
percentages of Mo-DC with expression of CD1a (p = 0.002), CD80 (p = 0.0005), CD83 (p = 0.0004), and
CD209 (p = 0.02) compared to healthy donors. There was an adverse correlation between WBC count and the
percentage of Mo-DC with co-expression of CD80 and CD86 (R = –0.63; p = 0.03). In patients treated with
TKI, we observed higher efficacy of DC generation in seven-day cultures, compared to untreated patients.
Expression of CD209 on DC was higher in patients treated with TKI (0.02). The duration of TKI therapy
correlated adversely with MFI for CD1a (R = –0.49; p = 0.006) and positively with MFI for CD83 (R = 0.63;
p = 0.01). Percentages of CD4+CD25highFoxP3+ cells (p = 0.0002) and Th17 cells (p = 0.02) were significantly
higher in untreated CML patients compared to healthy controls. There was a significant correlation between
the percentage of Treg cells and the percentage of peripheral blood basophiles (R = 0.821; p = 0.02). There
were no changes in Tregs or Th17 cell percentages in CML patients after six months of TKI therapy. However,
the expression of intracellular IL-17 in Th17 cells correlated negatively with the time of TKI therapy in the
whole group of treated patients (R = –0.516; p = 0.04). We noted a correlation between IL-6 serum level and
peripheral blood WBC count (R = 0.492; p = 0.04). There was also an inverse correlation between the serum
level of IL-6 and the duration of TKI therapy (R = –0.66; p = 0.03). Taken together, our data shows that
mature DC can be generated from CML patients treated with TKI, and that the yield of Mo-DC is higher in
patients treated with TKI than in patients with active disease. This should encourage further trials with DC
immunotherapy in patients with cytogenetic response after TKI therapy. We also found increased frequencies
of T regulatory and Th17 cells in CML patients, which might suggest their potential role in immunity against
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this disease. Further studies are needed to determine if manipulation of these cell populations might improve
the results of DC immunotherapy. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 1, pp. 153–160)
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Introduction
Immunotherapeutic strategies have a potential to in-
duce anti-tumor responses and are increasingly be-
ing explored in patients with hematological malig-
nancies. Dendritic cells (DC) are professional anti-
gen presenting cells, which are capable of initiating
specific immune responses and have a potential clini-
cal application [1]. For use in immunotherapy, den-
dritic cells are generated and pulsed with tumor-spe-
cific antigens under in vitro conditions [2, 3]. Usual-
ly, peripheral blood monocytes are used as DC pre-
cursors [4]. In patients with myeloid leukemias,
dendritic cells (DC) may originate from leukemic cells
and thus may also express leukemia-specific antigens.
Chronic myeloid leukemia (CML) is a clonal dise-
ase, characterized by a reciprocal t(9,22) chromosom-
al translocation resulting in a chimeric BCR/ABL
fusion gene that encodes an abnormal fusion protein
(p210) with a tyrosine kinase activity, which proba-
bly plays a key role in the pathogenesis of the disease
[5]. Imatinib mesylate is a specific inhibitor of of Abl
protein tyrosine kinases, which has been shown to
induce complete hematologic and cytogenetic res-
ponses in a significant proportion of patients [6] and
has become the standard first-line treatment for pa-
tients with chronic phase CML (CP-CML). Novel ty-
rosine kinase inhibitors (TKI) with greater therapeu-
tic potency, such as dasatinib, nilotinib and bosutinib
have been introduced into the management of pa-
tients with CML resistant to imatinib.
Immunotherapy with DC might constitute a new
and advantageous option for patients who respond
to TKI therapy, but do not reach complete cytoge-
netic or molecular remission. Initial clinical trials with
CML-derived DC (CML-DC) immunotherapy have
been reported [7–9] and have shown immune and
clinical responses in some patients [9]. The optimal
vaccination protocol for inducing anti-tumor respon-
ses using DC has not yet been established, meaning
that further studies into the biology of CML-DC are
still required, especially in the context of the influ-
ence of TKI therapy on CML-DC. Recent data has
shown that anti-tumor responses might be significant-
ly suppressed by T helper cells with regulatory func-
tions (Treg) [10], which suggests that the results of
DC vaccinations might also be negatively affected by
Treg [11]. More recent studies have revealed new
populations of T helper cells, such as Th17 cells [12],
whose role in tumor immunity remains unclear [13].
In the present study, we evaluated the immu-
nophenotype of Mo-DC generated from patients with
CML. Apart from the well known markers of DC
maturation, we also measured the expression of oth-
er molecules essential for DC function. And we evalu-
ated the influence of TKI therapy on the results of
CML-DC generation. We also measured the percent-
ages of Treg and the percentages of Th17 cells in un-




Between November 2007 and October 2009, 38 pa-
tients with CP-CML who were treated in the Hema-
tooncology and Bone Marrow Transplantation De-
partment of the Medical University of Lublin were
recruited into the study. Twenty healthy volunteers
were also recruited as a control group. The study was
approved by the Local Ethics Committee and all in-
dividuals gave their informed consent. From 19 pa-
tients, blood samples were taken at diagnosis before
the start of therapy. From 28 patients, samples were
taken during TKI therapy. Eighteen of these patients
were treated with imatinib at a dose of 400 mg, two
patients were treated with imatinib at a dose of 600
mg, four patients were treated with dasatinib at a dose
of 100 mg, and four patients were treated with bosu-
tinib at a dose of 500 mg. All the patients were in
complete cytogenetic remission at sampling. The cli-
nical characteristics of the patients are presented in
Table 1.
Methods
Generation of autologous DC from the peripheral blood
monocytes of CML patients
Peripheral blood mononuclear cells (PBMC) were iso-
lated from 40 ml heparinized peripheral blood sam-
ples by density gradient centrifugation (Gradisol-L,
Aqua Medica, Lodz, Poland). After isolation, the cells
were washed twice with PBS and incubated with anti-
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-CD14 microbeads (Miltenyi-Biotec, Bergisch Glad-
bach, Germany) and passed through MACS separa-
tion columns according to the manufacturer’s proto-
cols. The CD14 positive cell population was used to
prepare monocyte derived dendritic cells (Mo-DC).
The CD14+ cells were cultured in the appropriate
culture medium containing RPMI-1640 supplemen-
ted with 2% human albumin (Baxter), 100 IU/ml pen-
icillin, 50 mg/ml streptomycin and 100 mg/ml neo-
mycin (Sigma-Aldrich, Germany). On days 1, 3 and
5 of the culture, 1,000 IU/ml rhGM-CSF (Leukine,
Berlex, USA) and 500 IU/ml rhIL-4 (Miltenyi-Bio-
tec, Bergisch Gladbach, Germany) were added. Tu-
mor necrosis factor a (TNFa) at a concentration of
50 ng/ml and the lysates from CD33+ leukemic cells
were added during the last 48 hours of culture for
the maturation and pulsing of the DC. On day 8 of
the culture, DCs were harvested using Trypsin/EDTA
(Biochrom AG, Germany) solution. Their viability
was checked by Trypan Blue (Sigma-Aldrich, Germa-
ny) staining in light microscopy. Mature Mo-DC were
evaluated for the expression of CD1a, CD14, CD80,
CD83, CD86, CD206, CD209 and HLA-DR by flow
cytometry.
Flow cytometry analysis of T regulatory cells
Treg lymphocytes were estimated by Human Treg
Flow™ Kit (FOXP3 Alexa Fluor® 488/CD4 PECy5/
/CD25 PE, Biolegend, USA) according to the manu-
facturer’s protocol. Results are calculated as mean
CD4+/CD25+/FOXP3+ cells percentage in CD4+ gate
from triplicate counting for each sample.
Flow cytometry analysis of Th17 cells
Peripheral blood mononuclear cells (PBMCs) were
isolated by Gradisol L density gradient centrifuga-
tion. Cells were cultured at 2¥106 cells/ml in RPMI
1640 medium supplemented with 10% FBS, penicil-
lin and streptomycin. The cells were stimulated with
ionomycin (2 µg/ml) and phorbol myristate acetate
(PMA: 2.5 µg/ml) in the presence of brefeldin A
(2 µg/ml) for 4 hours at 37oC in an atmosphere con-
taining 5% CO2. Subsequently, cells were transferred
to tubes and washed once in PBS. Then the cells were
incubated with the monoclonal antibodies against
surface markers: FITC-conjugated anti-CD4 (Becton
Dickinson, USA) and PE-Cy5-conjugated anti-CD3
(Becton Dickinson, USA) for 20 minutes at room tem-
perature. Afterwards, cells were re-suspended in fixa-
tion and a permeabilization solution with Cytofix/
/Cytoperm according to the manufacturer’s protocol.
Then they were stained with PE-conjugated anti-IL-
-17 (eBioscience, USA) for 15 minutes at 4oC. We
analysed intracellular expression of  IL-17 in CD4+
cells among the lymphocyte-gate with the use of
BDFACS Calibur flow cytometer and CellQuest
software.
Analysis of IL-6 serum level
Serum concentration of IL-6 was measured according
to the manufacturer’s protocol using human IL-6
ELISA kit (Diaclone, UK) and multilabel plate reader
VICTORTM(PerkinElmer, USA).
Statistical analysis
Results are shown as mean value ± SD and median
followed by IQR (Interquartile Range). U Mann–Whit-
ney, Wilcoxon’s non-parametric tests and Spearman’s
rank correlation were used for statistical analysis.
Results
Results of DC generation in untreated
CML patients
We found that DC could be reliably generated from
the peripheral blood CD14+ cells of 19 untreated
CML patients. Seven-day cultures of monocytes in
the cytokines supplemented media resulted in the
Table 1. Clinical characteristics of the patients participating in the study
Number of patients 38
Gender (M/F) 26/12
Age (years); mean (range) 52.6 (24.0–77.0)
Number of untreated patients 19
Number of patients treated with imatinib 20
Duration of imatinib therapy (months); mean (range) 26.2 (6.0–65.0)
Number of patients treated with dasatinib 6
Duration of dasatinib therapy (months); mean (range) 10.0 (4.0–20.0)
Number of patients treated with bosutinib 4
Duration of bosutinib therapy (months); mean (range) 6.0 (6.0–6.0)
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generation of cells with a veiled appearance charac-
teristic for mature DC in light microscopy (data not
shown). The mean viability of generated DC was 93%
± 6%, and the median percentage of DC among the
cells in the culture was 23% (range 3.22–82.89%).
Analysis of the Mo-DC phenotype showed a per-
sistent expression of CD14 monocyte marker on DC
generated from monocytes of CML patients. The
percentage of CD14+ cells after seven-day culture was
significantly higher in CML patients compared to the
healthy controls (3.07% vs. 0.21%; p = 0.001). The
expression of CD14 measured as MFI (mean fluo-
rescence intensity) was also higher on the cells gene-
rated from untreated CML patients (p = 0.02).
The percentages of Mo-DC with expression of
CD1a (p = 0.002), CD80 (p = 0.0005), CD83
(0.0004), CD209 (p = 0.02) as well as with co-ex-
pression of CD1a/CD83; (p = 0.002), and CD80/
/CD86 (p = 0.04) were significantly lower in the CML
patients group (Figure 1).
Phenotypic analysis also showed significantly lower
expression of CD209 (MFI: 142.0 vs. 2790.0; p =
= 0.02) on DC from the CML patients compared to
the healthy controls.
There was an adverse correlation between WBC
count and the percentage of Mo-DC with co-expres-
sion of CD80 and CD86 (R = –0.63; p = 0.03).
In patients treated with TKI, in comparison with
untreated CML patients, we observed higher effica-
cy of DC generation in seven-day cultures. The me-
dian percentage of DC among the cells in the culture
was 30.7% (range: 3.22–82.89%) and was significantly
higher than in untreated patients.
The percentage of cells with CD14 expression was
significantly lower in the patients treated with TKI
(p = 0.0008), compared to untreated ones (Figure 1).
Expression of CD209 on DC was higher compared
to untreated patients with CML (MFI: 948.0 vs.
179.0; p = 0.02).
The time of TKI therapy correlated adversely with
MFI for CD1a (R = –0.49; p = 0.006) and positively
with MFI for CD83 (R = 0.63; p = 0.01).
In nine patients, analysis performed before, and
six months after, TKI therapy showed a significant
decrease only in the percentage of CD14+ Mo-DC
(p = 0.03). The expression of CD14 measured as MFI
was also significantly lower (p = 0.03). In contrast,
Mo-DC expressed a significantly higher amount of
CD83 (p = 0.03).
Analysis of Treg cells in peripheral blood of CP-CML
patients
The percentage of CD4+CD25highFoxP3+ cells was sig-
nificantly higher in untreated CML patients com-
pared to healthy controls (p = 0.0002) (Figure 2).
There was a significant correlation between the per-
centage of Tregs and the percentage of peripheral
blood basophiles (R = 0.821; p < 0.05). There was
no significant change in the Treg percentage in CML
patients after six months of TKI therapy.
 Analysis of Th17 cells percentages in peripheral blood
of CP-CML patients
The percentage of Th17 cells was significantly high-
er in untreated CML patients compared to healthy
controls (p = 0.02) (Figure 3). There was no signifi-
cant change in the Th17 cells percentage in CML
patients after six months of TKI therapy. But expres-
sion of intracellular IL-17 correlated negatively with
the time of TKI therapy in the whole group of trea-
ted patients (R = –0.516; p = 0.02).
Analysis of IL-6 level in serum of CP-CML patients
There was no significant difference between the con-
centration of IL-6 in untreated CML patients and in
the healthy controls. However, we noted a correla-
tion between IL-6 serum level and peripheral blood
Figure 1. Values of measured parameters describing the immunophenotype of Mo-DC (UnT — untreated CML
patients; TKI CML — CML patients treated with TKI; HD — healthy donors). Statistical analysis described in text
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WBC count (R = 0.492; p = 0.04). There was also an
inverse correlation between serum level of IL-6 and
the time of TKI therapy (R = –0.66; p = 0.03).
Discussion
Therapeutic approaches combining TKI with active
DC immunotherapy might become a valuable option
for patients with CML not achieving complete cyto-
genetic or molecular remission after TKI therapy. For
the development of efficient immunotherapy proto-
cols, detailed knowledge as to the effect of TKI on
Mo-DC generation, as well as T cell populations, is
required.
In this study, we compared the immunophenotype
of Mo-DC generated from untreated patients with
CML, from patients with CML treated with TKI, and
from healthy donors.
We confirmed that DC could be efficiently diffe-
rentiated from peripheral blood monocytes of CML
patientxs [9, 14]. The yield of generated DC was lo-
wer compared to healthy donors, with some differen-
ces noted in surficial markers, such as lower percen-
tages of cells with expression of CD1a, CD80 and
CD83, CD206 and CD209. Previous studies on Mo-DC
from CML patients have revealed divergent results.
Eisendle et al. showed lower expression of CD80,
CD83, CD86 on LPS maturated DC [4], which was
improved when IL-1b, TNF-a and PGE2 were used.
DC cells maturated with a cytokine cocktail were ful-
ly functional in a mixed leukocyte reaction (MLR),
something also found in a study by Westermann et
al. [9]. Dong et al. showed high expression of matu-
ration markers (CD80, CD86 HLA-DR) with IL-1b
and TNF used for maturation. However, DC were
defective in mannose receptor mediated endocytosis
and macropinocytosis [15]. Significantly lower expres-
sion of CD206 (mannose receptor C type-1) and
CD209 (DC-SIGN; DC-specific, ICAM-3 grabbing
noninegrin) on Mo-DC maturated with TNF might
be connected with impaired antigen capture observed
by Dong et al.
These results suggest the need for further investi-
gation to find the optimal generation conditions for
Mo-DC from CML patients.
Results of Mo-DC generation from patients in
complete cytogenetic remission after TKI therapy
showed an improved yield of DC in seven-day cul-
tures compared to the patients with active disease.
We also found increased CD83 and CD209 expres-
sion, together with decreased CD1a expression. Most
studies published so far have evaluated the effect of
imatinib on DC generation when the drug was given
Figure 3. Differences in circulating CD4+/CD25+/FoxP3+
Tregs; A. and Th17 cells; B. between untreated CML
patients and healthy donors
Figure 2. Significant changes in the immunophenotype of
Mo-DC after TKI treatment; A. percentage of
CD45+CD14+ cells and MFI of CD14; B. MFI of CD83;
(UnT CML — before TKI treatment; 6m. Treatment —
after six months of TKI treatment)
158 I Hus et al.
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2011
10.5603/FHC.2011.0022
www.fhc.viamedica.pl
to the culture of dendritic cells, but not in patients
treated with imatinib. It has been shown that in the
culture, imatinib impairs the differentiation of DC,
both from 34+ progenitor cells and monocytes, re-
sulting in low expression of DC-associated cell sur-
face molecules like CD1a and CD83, and costimula-
tion molecules like CD80 and CD40 [16, 17]. Beside
these phenotype alterations, the cells were unable to
elicit primary T-cell responses as well as responses to
recall antigens. Moreover, DC incubated with ima-
tinib had a reduced endocytosis activity [16]. These
in vitro observations have been confirmed by data from
a mouse model [18]. In contrast, it has also been
shown that imatinib does not affect CML-DC phe-
notype, migration profile or T-cell stimulatory capa-
city [19] and CML-DC display even improves anti-
gen presentation abilities in the presence of imatinib
[20]. In mice, DC treated with imatinib have exhibit-
ed enhanced APC function [21]. Limited studies in-
vestigating the impact of imatinib on na1¨ve human
blood DC have revealed that imatinib impairs nei-
ther the immunophenotype profile nor the DC-me-
diated polarization of na1¨ve CD4+ T cells [22, 23].
In one study, where DC were generated from CML
patients treated with TKI, there was an increase of
CD1a, CD80, and CD86 compared to the parent
population, but not to healthy donors. The authors
showed that DC become BCR-ABL negative in CML
patients treated successfully with imatinib [24], which
might be advantageous because leukemic cells do not
process antigen normally in CML [15]. It seems that
more studies are needed into the immunophenotype
and function of Mo-DC generated from patients trea-
ted with TKI in order to evaluate the use of Mo-DC
immunotherapy in combination with TKI.
Next, we evaluated the percentage of T regulato-
ry cells in CML patients, and found that it was signifi-
cantly higher compared to healthy controls. Increased
numbers of Tregs have previously been found in pe-
ripheral blood of cancer patients as well as in malig-
nant effusions [25, 26]. Recent studies have docu-
mented that Tregs suppress tumor-specific T-cell im-
munity, and therefore might contribute to the pro-
gression of human tumors [10]. There is very limited
data regarding T regulatory cells in CML. Nadal et
al. found that increased frequencies of Treg correlate
with disease relapse after allogeneic stem cell trans-
plantation [27]. However, increased populations of
CD4+CD25high regulatory T cells have been found in
acute myeloid leukemia (AML) patients [28, 29] and
depletion of T regulatory cells dramatically improved
the efficacy of DC vaccines in a preclinical AML
murine model [30]. In the context of potential use of
DC immunotherapy in patients treated with TKI, it
would be useful to know how imatinib therapy af-
fects Tregs. In our studies, there were no significant
changes of Treg frequencies in imatinib-treated pa-
tients. However, in vitro studies showed that imatinib
[31] and dasatinib impaired the proliferation and
function of CD4+CD25+ regulatory cells in a dose-
-dependent manner [32]. Further studies into the
function of Tregs in patients treated with TKI are nee-
ded, especially given that encouraging data in a mouse
model showed that imatinib enhanced active immu-
notherapy against BCR-ABL+ tumors [33, 34].
Finally, we analyzed the percentages of Th17 cells
in peripheral blood of CML patients. Th17 cells rep-
resent a novel subset of T helper cells that play an
active role in inflammatory and autoimmune disea-
ses [35]. Recent studies in solid tumors have also sug-
gested the impact of Th17 cells, both in carcinogenesis
and anti-cancer responses [36, 37]. Their role is prob-
ably complex and divergent, depending on the clini-
cal stage and the role of angiogenesis and inflamma-
tion in tumor pathogenesis.
There has been no data published to date on
Th17 in chronic myeloid leukemia. We found a sig-
nificantly higher percentage of Th17 cells in untrea-
ted patients with CML than in healthy controls, and
that this percentage decreased after six months of
imatinib therapy. Though the decrease was not sig-
nificant, there was a negative correlation between
the expression of intracellular IL-17 in Th17 cells
and the time of TKI therapy in the whole group of
patients treated with TKI from four to 70 months.
IL-6 belongs to important growth factors for Th17
in mice, and probably also in humans [38, 39]. Al-
though we did not find a direct correlation between
IL-6 serum level and Th17 cell percentage, there
was a correlation between IL-6 and WBC count in
untreated CML patients, and a negative correlation
between IL-6 and the time of treatment in patients
treated with TKI. Increased IL-6 level has been pre-
viously shown in CML patients [40, 41] and in pa-
tients with AML. Moreover, in AML patients, there
was a positive correlation between high IL-6 con-
centration and increased percentage of Th17 cells
[42, 43]. High frequencies of Th17 cells were reduced
when patients achieved complete remission after
chemotherapy, suggesting that measurement of
Th17 frequencies might have a clinical value in eva-
luating the effects of therapy. Such preliminary data
suggests that Th17 cells might participate in the
development of CML, although their role in this
disease, and their potential role in immunotherapy, is
yet to be established.
Taken together, our data shows that mature DC
can be generated from CML patients treated with
159Mo-DC, Tregs and Th17 in CML patients treated with TKI
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2011
10.5603/FHC.2011.0022
www.fhc.viamedica.pl
TKI, and that the yield of Mo-DC is higher com-
pared to untreated patients, which should encour-
age further trials with DC immunotherapy in pa-
tients with cytogenetic response after TKI therapy.
We also found increased frequencies of T regulato-
ry and Th17 cells in CML patients, which might sug-
gest a potential role in immunity from this disease.
Further studies are needed to establish if manipula-
tion of these populations  might improve the results
of DC immunotherapy.
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